Spoken Alpha
Niagen Bioscience, Inc.
Niagen Bioscience provides dietary supplements and ingredient technologies focused on nicotinamide riboside, a NAD+ precursor that supports cellular health and healthy aging.
Niagen Bioscience, Inc is a Consumer Defensive company operating in Packaged Foods with a $239.4M market cap.
Most recent reported earnings: Q3 FY2026 (Nov 2, 2026).
19 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for NAGE.
$ curl https://api.spokenalpha.com/v1/companies/NAGEFAQ
Spoken Alpha indexes NAGE's earnings call transcripts at https://spokenalpha.com/companies/NAGE. Each call links to attributed speakers and parsed analyst Q&A. Niagen Bioscience, Inc.'s own investor relations page is at https://investors.niagenbioscience.com/overview/default.aspx.
Niagen Bioscience, Inc. (NAGE) held its most recent earnings call on 2026-05-06, covering fiscal Q1 2026.
Niagen Bioscience, Inc. (NAGE) operates in the Consumer Defensive sector (Packaged Foods industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-02 | — | $0.00 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-03 | $0.01 | $0.01 | 0.0% | $29.8M | — | — | EODHD |
| Q1 FY2026 | 2026-05-05 | $0.02 | $0.06 | -66.7% | $31.5M | — | — | EODHD |
| Q4 FY2025 | 2026-03-10 | $0.03 | $0.02 | +25.4% | $33.8M | — | — | EODHD |
| Q3 FY2025 | 2025-11-03 | $0.05 | $0.02 | +100.0% | $34.0M | — | — | EODHD |
| Q2 FY2025 | 2025-08-05 | $0.04 | $0.01 | +100.0% | $31.1M | — | — | EODHD |
| Q1 FY2025 | 2025-05-06 | $0.05 | $0.02 | +100.0% | $30.5M | — | — | EODHD |
| Q4 FY2024 | 2025-03-03 | $0.09 | $0.02 | +100.0% | $29.1M | — | — | EODHD |
| Q3 FY2024 | 2024-10-30 | $0.02 | $0.01 | +100.0% | $25.6M | — | — | EODHD |
| Q2 FY2024 | 2024-08-06 | $0.02 | $-0.01 | +100.0% | $22.7M | — | — | EODHD |
| Q1 FY2024 | 2024-05-07 | $-0.01 | $-0.01 | 0.0% | $22.2M | — | — | EODHD |
| Q4 FY2023 | 2024-03-05 | $0.00 | $-0.02 | +100.0% | $21.2M | — | — | EODHD |
| Q3 FY2023 | 2023-11-07 | $-0.01 | $-0.03 | +66.7% | $19.5M | — | — | EODHD |
| Q2 FY2023 | 2023-08-08 | $-0.03 | $-0.04 | +25.0% | $20.3M | — | — | EODHD |
| Q1 FY2023 | 2023-05-09 | $-0.03 | $-0.05 | +40.0% | $22.6M | — | — | EODHD |
| Q4 FY2022 | 2023-03-07 | $-0.02 | $-0.02 | 0.0% | $21.0M | — | — | EODHD |
| Q3 FY2022 | 2022-11-01 | $-0.01 | $-0.06 | +83.3% | $17.1M | — | — | EODHD |
| Q2 FY2022 | 2022-08-09 | $-0.09 | $-0.09 | 0.0% | $16.7M | — | — | EODHD |
| Q1 FY2022 | 2022-05-11 | $-0.11 | $-0.09 | -22.2% | $17.3M | — | — | EODHD |
| Q4 FY2021 | 2022-03-08 | $-0.08 | $-0.08 | 0.0% | $17.8M | — | — | EODHD |
Source: EODHD. NAGE reported actuals as published; sparse fields render as —.